Persivia vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $107M strategic (May 2025) from Aldrich Capital. 200+ hospitals, 12,000+ clinicians. Patented Soliton AI engine. Global expansion in 2026. Spans care management, population health, and RCM.
About
Persivia is a unified AI healthcare platform spanning care management, population health analytics, and revenue cycle operations — one of the few integrated platforms that addresses both the clinical and financial sides of health system performance simultaneously. The company raised $107 million in strategic financing from Aldrich Capital Partners in May 2025, and is actively expanding globally in 2026 with its CareSpace platform deployed at 200+ hospitals and used by 12,000+ clinicians.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.